CCL2/CCL5 Secreted by the Stroma Induce IL-6/PYK2 Dependent Chemoresistance in Ovarian Cancer

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2018 Feb 20

PMID 29455640

Citations 46

Authors

Jennifer Pasquier

Marie Gosset

Caroline Geyl

Jessica Hoarau-Vechot

Audrey Chevrot

Marc Pocard

Massoud Mirshahi

Raphael Lis

Arash Rafii

Cyril Touboul

Affiliations

Soon will be listed here.

Abstract

Background: Minimal residual disease is the main issue of advanced ovarian cancer treatment. According to the literature and previous results, we hypothesized that Mesenchymal Stromal Cells (MSC) could support this minimal residual disease by protecting ovarian cancer cells (OCC) from chemotherapy. In vitro study confirmed that MSC could induce OCC chemoresistance without contact using transwell setting. Further experiments showed that this induced chemoresistance was dependent on IL-6 OCC stimulation.

Methods: We combined meticulous in vitro profiling and tumor xenograft models to study the role of IL-6 in MSC/OCC intereactions.

Results: We demonstrated that Tocilizumab® (anti-IL-6R therapy) in association with chemotherapy significantly reduced the peritoneal carcinosis index (PCI) than chemotherapy alone in mice xenografted with OCCs+MSCs. Further experiments showed that CCL2 and CCL5 are released by MSC in transwell co-culture and induce OCCs IL-6 secretion and chemoresistance. Finally, we found that IL-6 induced chemoresistance was dependent on PYK2 phosphorylation.

Conclusions: These findings highlight the potential key role of the stroma in protecting minimal residual disease from chemotherapy, thus favoring recurrences. Future clinical trials targeting stroma could use anti-IL-6 therapy in association with chemotherapy.

Citing Articles

Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival.

Mora-Lagos B, Reyes M, Lobos-Gonzalez L, Del Campo M, Buchegger K, Zanella L Biol Res. 2025; 58(1):4.

PMID: 39827154 PMC: 11748569. DOI: 10.1186/s40659-024-00581-3.

Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden.

Provenzano L, Gwee Y, Conca V, Lonardi S, Bozzarelli S, Tamburini E Ther Adv Med Oncol. 2024; 16:17588359241289517.

PMID: 39502404 PMC: 11536604. DOI: 10.1177/17588359241289517.

Exploring the Potential of Natural Killer Cell-Based Immunotherapy in Targeting High-Grade Serous Ovarian Carcinomas.

Kaur K, Sanghu J, Memarzadeh S, Jewett A Vaccines (Basel). 2024; 12(6).

PMID: 38932405 PMC: 11209217. DOI: 10.3390/vaccines12060677.

Integrin αVβ1-activated PYK2 promotes the progression of non-small-cell lung cancer via the STAT3-VGF axis.

Wu Z, Jiao M, Shu C, Zhang S, Wang J, Pu J Cell Commun Signal. 2024; 22(1):313.

PMID: 38844957 PMC: 11157819. DOI: 10.1186/s12964-024-01639-1.

Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis.

Dadgar N, Sherry C, Zimmerman J, Park H, Lewis C, Donnenberg A J Transl Med. 2024; 22(1):402.

PMID: 38689325 PMC: 11061933. DOI: 10.1186/s12967-024-05205-8.

References

Touboul C, Lis R, Al Farsi H, Raynaud C, Warfa M, Althawadi H . Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model. J Transl Med. 2013; 11:28. PMC: 3582577. DOI: 10.1186/1479-5876-11-28. View

Ghiabi P, Jiang J, Pasquier J, Maleki M, Abu-Kaoud N, Halabi N . Breast cancer cells promote a notch-dependent mesenchymal phenotype in endothelial cells participating to a pro-tumoral niche. J Transl Med. 2015; 13:27. PMC: 4336716. DOI: 10.1186/s12967-015-0386-3. View

Milagre C, Gopinathan G, Everitt G, Thompson R, Kulbe H, Zhong H . Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer. Cancer Res. 2015; 75(7):1255-64. PMC: 4384986. DOI: 10.1158/0008-5472.CAN-14-1801. View

Benabbou N, Mirshahi P, Cadillon M, Soria J, Therwath A, Mirshahi M . Hospicells promote upregulation of the ATP-binding cassette genes by insulin-like growth factor-I via the JAK2/STAT3 signaling pathway in an ovarian cancer cell line. Int J Oncol. 2013; 43(3):685-94. PMC: 3787860. DOI: 10.3892/ijo.2013.2017. View

Shimizu T, Fukuoka K, Takeda M, Iwasa T, Yoshida T, Horobin J . A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016; 77(5):997-1003. PMC: 4844649. DOI: 10.1007/s00280-016-3010-1. View

Shah N, Tancioni I, Ward K, Lawson C, Chen X, Jean C . Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecol Oncol. 2014; 134(1):104-11. PMC: 4065804. DOI: 10.1016/j.ygyno.2014.04.044. View

Meads M, Gatenby R, Dalton W . Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009; 9(9):665-74. DOI: 10.1038/nrc2714. View

Xu W, Bian Z, Fan Q, Li G, Tang T . Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett. 2009; 281(1):32-41. DOI: 10.1016/j.canlet.2009.02.022. View

Levano K, Jung E, Kenny P . Breast cancer subtypes express distinct receptor repertoires for tumor-associated macrophage derived cytokines. Biochem Biophys Res Commun. 2011; 411(1):107-10. DOI: 10.1016/j.bbrc.2011.06.102. View

10.

Guerrouahen B, Pasquier J, Kaoud N, Maleki M, Beauchamp M, Yasmeen A . Akt-activated endothelium constitutes the niche for residual disease and resistance to bevacizumab in ovarian cancer. Mol Cancer Ther. 2014; 13(12):3123-36. DOI: 10.1158/1535-7163.MCT-13-1053. View

11.

Pasquier J, Abu-Kaoud N, Abdesselem H, Madani A, Hoarau-Vechot J, Al Thawadi H . SDF-1alpha concentration dependent modulation of RhoA and Rac1 modifies breast cancer and stromal cells interaction. BMC Cancer. 2015; 15:569. PMC: 4522077. DOI: 10.1186/s12885-015-1556-7. View

12.

Tancioni I, Uryu S, Sulzmaier F, Shah N, Lawson C, Miller N . FAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth. Mol Cancer Ther. 2014; 13(8):2050-61. PMC: 4126870. DOI: 10.1158/1535-7163.MCT-13-1063. View

13.

Al Thawadi H, Abu-Kaoud N, Al Farsi H, Hoarau-Vechot J, Rafii S, Rafii A . VE-cadherin cleavage by ovarian cancer microparticles induces β-catenin phosphorylation in endothelial cells. Oncotarget. 2015; 7(5):5289-305. PMC: 4868686. DOI: 10.18632/oncotarget.6677. View

14.

Zimmerlin L, Park T, Zambidis E, Donnenberg V, Donnenberg A . Mesenchymal stem cell secretome and regenerative therapy after cancer. Biochimie. 2013; 95(12):2235-45. PMC: 3825748. DOI: 10.1016/j.biochi.2013.05.010. View

15.

Lis R, Touboul C, Raynaud C, Malek J, Suhre K, Mirshahi M . Mesenchymal cell interaction with ovarian cancer cells triggers pro-metastatic properties. PLoS One. 2012; 7(5):e38340. PMC: 3364218. DOI: 10.1371/journal.pone.0038340. View

16.

Mirza M, Monk B, Herrstedt J, Oza A, Mahner S, Redondo A . Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016; 375(22):2154-2164. DOI: 10.1056/NEJMoa1611310. View

17.

Meads M, Fang B, Mathews L, Gemmer J, Nong L, Rosado-Lopez I . Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma. Oncogene. 2015; 35(21):2723-34. PMC: 4801703. DOI: 10.1038/onc.2015.334. View

18.

Anton K, Banerjee D, Glod J . Macrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretion. PLoS One. 2012; 7(4):e35036. PMC: 3319627. DOI: 10.1371/journal.pone.0035036. View

19.

Kidd S, Spaeth E, Dembinski J, Dietrich M, Watson K, Klopp A . Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 2009; 27(10):2614-23. PMC: 4160730. DOI: 10.1002/stem.187. View

20.

Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster D . Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res. 2011; 17(18):6083-96. PMC: 3182554. DOI: 10.1158/1078-0432.CCR-11-0945. View